Aurinia Pharmaceuticals (AUPH) vs. Fortress Biotech (FBIO) Financial Contrast

Aurinia Pharmaceuticals (AUPH) vs. Fortress Biotech (FBIO) Financial Contrast

Aurinia Pharmaceuticals and Fortress Biotech are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and valuation. Aurinia Pharmaceuticals presently has a consensus target price of $12.17, indicating a potential upside of 117.65%.

from Biotech News